On Wednesday, Aramark (NYSE:ARMK)’s shares inclined 1.79% to $32.39.
Aramark and 77 of its higher education partners recycled more than 16.6 million pounds of waste in the 2015 RecycleMania competition, an annual competition for college and university recycling programs aimed at promoting waste reduction on campuses.
Aramark, (ARMK), the $15 billion global provider of award-winning services in food, facilities administration and uniforms, collaborates with its higher education clients each year as part of its commitment to environmental sustainability, with waste minimization efforts being a major focus. RecycleMania provides an opportunity for Aramark and its partners to celebrate their progress in minimizing waste, and recognize the accomplishments of the colleges and universities that take part.
Aramark provides food, facilities, and uniform services to education, healthcare, business and industry, sports, leisure, and corrections clients primarily in North America. The company offers managed services, counting dining, catering, food service administration, convenience-oriented retail operations, grounds and facilities maintenance, custodial, energy and construction administration, and capital project administration. It also provides non-clinical support services, such as patient food and nutrition, and retail food services; and facilities services comprising clinical equipment maintenance, environmental, laundry and linen distribution, plant operations, planned/technical, energy and supply chain administration, purchasing, and central transportation.
Second Sight Medical Products Inc (NASDAQ:EYES)’s shares gained 6.60% to $14.37.
Second Sight Medical Products, Inc. (EYES) a developer, manufacturer and marketer of implantable visual prosthetics that restore some useful vision to blind patients, recently declared the first implant and successful activation of the Argus® II Retinal Prosthesis System (Argus II) in a dry age-related macular degeneration (AMD) patient.
The implant is part of a feasibility study which aims to evaluate the safety and utility of the Argus II System in individuals with late-stage Dry AMD, a condition that severely affects their central vision. The implant was performed at the Manchester Royal Eye Hospital in the United Kingdom by Dr. Paulo Stanga MD, Consultant Ophthalmologist & Vitreoretinal Surgeon at the Manchester Royal Eye Hospital, Professor of Ophthalmology and Retinal Degeneration at The University of Manchester. The device was activated about two weeks after implantation, and initial reports confirm that the subject is receiving some useful vision from the Argus II system. The Argus II has already been tested and approved in the United States and Europe for individuals with Retinitis Pigmentosa (RP) and Outer Retinal Degeneration, respectively.
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the United States, Canada, Europe, and Saudi Arabia. It offers Argus II System, an implantable neurostimulation device that uses electrical stimulation of the retina to replace the function of the defunct photo-receptors in retinitis pigmentosa patients. Second Sight Medical Products, Inc. sells its Argus II System to university hospitals, teaching hospitals, medical centers, and ambulatory surgical centers.
At the end of Wednesday’s trade, Fidelity National Financial Inc (NYSE:FNF)‘s shares surged 0.82% to $38.24.
Fidelity National Financial, Inc. recently declared that its Board of Directors has declared an raised FNF Group (FNF) quarterly cash dividend of $0.21 per share, a 10.5% enhance from the previous quarterly dividend of $0.19. The dividend will be payable September 30, 2015, to stockholders of record as of September 16, 2015.
Fidelity National Financial, Inc., together with its auxiliaries, provides title insurance, technology, and transaction services to the real estate and mortgage industries in the United States. It operates through Title, BKFS, and Restaurant Group segments. The Title segment offers title insurance, escrow, and other title related services, counting collection and trust activities, trustees sales guarantees, recordings and reconveyances, and home warranty insurance.
Perrigo Company plc Ordinary Shares (NYSE:PRGO), ended its Wednesday’s trading session with 1.06% gain, and closed at $189.05.
Perrigo Company plc (PRGO) declared that it has reached a contract to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is predictable to generate about €30 million in full year 2015 net sales. Yokebe, the second largest dietary brand (by market share) in Germany, comes in a shake/liquid form and is marketed within the ‘meal replacement’ category.
The acquisition is predictable to be right away accretive to Perrigo’s calendar 2015 adjusted earnings per share and to exceed Perrigo’s ROIC threshold in calendar year 2016. The transaction has been unanimously approved by the Boards of Directors of Perrigo and Naturwohl Pharma, and is predictable to close in the third quarter, pending German regulatory approval and the satisfaction of customary closing conditions.
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, in addition to in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
